By Puyaan Singh and Michael Erman Dec 16 (Reuters) - Pfizer said on Tuesday the next few years will be bumpy, beginning with ...

Pfizer Inc. forecast little to no sales growth next year as the drugmaker undertakes an effort to refresh its pipeline of hit ...

Pfizer CEO Albert Bourla defended his company’s vaccine business as rhetoric from HHS Secretary Robert F. Kennedy Jr. drives ...

Alongside its cost-cutting strategy, Pfizer has been investing into its cardiometabolic pipeline in a bid to enter the ...

Built into the 2026 guidance is a $1.5 billion decline in sales of its COVID products—from an estimated $6.5 billion this ...

With $6 billion left in firepower, Pfizer is planning transactions in the hundreds of millions to the low-billions range, ...

Pfizer’s recent bidding war for an obesity biotech clearly hasn’t satiated the pharma’s appetite for new GLP-1 therapies—at least going by ...

Pfizer (PFE) is reiterated as a Buy, supported by the world's largest drug pipeline and trading below intrinsic value, ...

Pfizer's stock has fallen by more than 50% from its 2021 highs and faces some headwinds, but remains worth a deep dive for long-term investors.

Pfizer is paying top dollar for a GLP-1 candidate from Fosun Pharma. Zealand Pharma penned a platform deal with brand new ...

Fosun Pharmaceutical is a spinoff from Fosun International, which is chaired by China billionaire chairman Guo Guangchang; ...

(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.) Dec 12 (Reuters) - Pfizer’s Tukysa added to maintenance therapy significantly ...